Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Cross

Showing results (521-530 of 556) with videos related to

Pageof 56
Sort By:
Multiple Sclerosis and Related Disorders|June 25, 2023
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trialMitzi J Williams, Annette F Okai, Anne H Cross, et al.
Neurology|June 18, 2013
Genetic risk variants in African Americans with multiple sclerosisNoriko Isobe, Pierre-Antoine Gourraud, Hanne F Harbo, et al.
Neurology|November 3, 2017
High risk of postpartum relapses in neuromyelitis optica spectrum disorderEric C Klawiter, Riley Bove, Liene Elsone, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 7, 2017
Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter studyRiley Bove, Liene Elsone, Enrique Alvarez, et al.
Plos Genetics|May 10, 2014
A dominant-negative mutation of mouse Lmx1b causes glaucoma and is semi-lethal via LDB1-mediated dimerization [corrected]Sally H Cross, Danilo G Macalinao, Lisa McKie, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 yearsStephen L Hauser, Anne H Cross, Kevin Winthrop, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
The Journal of Clinical Investigation|January 2, 2025
A single-cell compendium of human cerebrospinal fluid identifies disease-associated immune cell populationsClaudia Cantoni, Roman A Smirnov, Maria Firulyova, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 16, 2026
Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple SclerosisRoman A Smirnov, Claudia Cantoni, Kenneth Lee, et al.
Nature Communications|April 5, 2022
Immunosuppressive niche engineering at the onset of human colorectal cancerChandler D Gatenbee, Ann-Marie Baker, Ryan O Schenck, et al.
Pageof 56

Showing results (521-530 of 556) with videos related to

Sort By:
Pageof 56
Multiple Sclerosis and Related Disorders|June 25, 2023
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trialMitzi J Williams, Annette F Okai, Anne H Cross, et al.
Neurology|June 18, 2013
Genetic risk variants in African Americans with multiple sclerosisNoriko Isobe, Pierre-Antoine Gourraud, Hanne F Harbo, et al.
Neurology|November 3, 2017
High risk of postpartum relapses in neuromyelitis optica spectrum disorderEric C Klawiter, Riley Bove, Liene Elsone, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 7, 2017
Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter studyRiley Bove, Liene Elsone, Enrique Alvarez, et al.
Plos Genetics|May 10, 2014
A dominant-negative mutation of mouse Lmx1b causes glaucoma and is semi-lethal via LDB1-mediated dimerization [corrected]Sally H Cross, Danilo G Macalinao, Lisa McKie, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 yearsStephen L Hauser, Anne H Cross, Kevin Winthrop, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
The Journal of Clinical Investigation|January 2, 2025
A single-cell compendium of human cerebrospinal fluid identifies disease-associated immune cell populationsClaudia Cantoni, Roman A Smirnov, Maria Firulyova, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 16, 2026
Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple SclerosisRoman A Smirnov, Claudia Cantoni, Kenneth Lee, et al.
Nature Communications|April 5, 2022
Immunosuppressive niche engineering at the onset of human colorectal cancerChandler D Gatenbee, Ann-Marie Baker, Ryan O Schenck, et al.
Pageof 56